Denali Therapeutics has been granted a patent for proteins capable of crossing the blood-brain barrier and containing SGSH enzyme-Fc fusion polypeptides. These proteins can be used to treat Sanfilippo syndrome A. GlobalData’s report on Denali Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Denali Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Denali Therapeutics's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Proteins for treating sanfilippo syndrome a
A recently granted patent (Publication Number: US11884944B2) discloses a protein comprising two fusion polypeptides linked to Fc polypeptides and N-sulfoglucosamine sulfohydrolase (SGSH) amino acid sequences. The protein is designed to enhance the uptake of the SGSH amino acid sequence into the brain, with at least a four-fold increase compared to the uptake of the unmodified SGSH enzyme. Importantly, the protein does not contain immunoglobulin heavy and/or light chain variable region sequences or antigen-binding portions, making it a unique therapeutic agent.
Furthermore, the patent includes claims for pharmaceutical compositions containing the described protein and a pharmaceutically acceptable excipient. The compositions aim to leverage the enhanced brain uptake capabilities of the protein for potential therapeutic applications. The specific sequences of the fusion polypeptides are detailed in the claims, providing a clear roadmap for the development and production of the protein-based pharmaceutical compositions. Overall, the patent highlights a novel protein design with promising implications for targeted drug delivery to the brain, potentially opening up new avenues for treating neurological disorders.
To know more about GlobalData’s detailed insights on Denali Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
